PPM1G — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL4697866	0.89	2/20
SCHEMBL4697696	0.86	2/20
SCHEMBL4698636	0.76	2/20
SCHEMBL4699183	0.74	2/20
SCHEMBL4696222	0.72	2/20
SCHEMBL4920392	0.66	2/20
SCHEMBL4701647	0.62	2/20
SCHEMBL4919390	0.61	2/20
SCHEMBL14070215	0.59	2/20
SCHEMBL14070277	0.58	2/20
Hydrochloric Acid (SCHEMBL5484384)	0.39	2/20
Molibresib (SCHEMBL1872390)	1.00	1/20
Molibresib (SCHEMBL12671490)	1.00	1/20
Molibresib (SCHEMBL12966358)	1.00	1/20
SCHEMBL9998851	0.91	1/20
SCHEMBL14756282	0.88	1/20
SCHEMBL12966165	0.87	1/20
SCHEMBL14756215	0.87	1/20
SCHEMBL14756339	0.87	1/20
SCHEMBL9998825	0.86	1/20

Clinical trials — most relevant to PPM1G by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Rectal Tacrolimus in the Treatment of Resistant Ulcerative Proctitis	PHASE4	COMPLETED
Rapamycin Treatment for Activated Phosphoinositide 3-Kinase δ Syndrome	PHASE1/PHASE2	COMPLETED
Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC Patients	PHASE2	COMPLETED
Temsirolimus With or Without Megestrol Acetate and Tamoxifen Citrate in Treating Patients With Advanced, Persistent, or Recurrent Endometrial Cancer	PHASE2	COMPLETED
Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)	PHASE1/PHASE2	WITHDRAWN
Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer	PHASE1/PHASE2	RECRUITING
Pembrolizumab Plus Enfortumab Vedotin in Collecting Duct and Renal Medullary Carcinoma	PHASE2	RECRUITING
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Sirolimus to Treat Cowden Syndrome and Other PTEN Hamartomatous Tumor Syndromes	PHASE2	COMPLETED
The Phosphodiesterase 4 Inhibitor Roflumilast as an Adjunct to Antidepressants in Major Depressive Disorder Patients	PHASE1/PHASE2	WITHDRAWN
RAD001 in Pheochromocytoma or Nonfunctioning Carcinoid	PHASE2	COMPLETED
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Arsenic Trioxide and Pamidronate in Treating Patients With Advanced Solid Tumors or Multiple Myeloma	PHASE1	COMPLETED
Evaluating MED2005 & Nitrostat Bioavailability	PHASE1	COMPLETED
Phase I Study of SC-43 Oral Solution in Subjects With Refractory Solid Tumors	PHASE1	WITHDRAWN
Bioequivalence Study of Tacrolimus in Healthy Volunteers	PHASE1	COMPLETED
Palliative Thoracic Radiotherapy Plus BKM120	PHASE1	COMPLETED
Lymphoid Tyrosine Phosphatase Gene Polymorphisms in Inflammatory Bowel Disease	nan	UNKNOWN
Quantification of GADD34 Expression in RA	nan	COMPLETED
NGS in Gallbladder Cancer and Response to Treatment	nan	RECRUITING
Duality of Lipids: the Athlete's Paradox	nan	COMPLETED
Immune Signature of Palmoplantar Pustulosis	nan	COMPLETED
p-AKT Expression on Clinical Outcomes in Malignant Lymphoma	nan	COMPLETED
Clinical, Genetic, and Epidemiologic Study of Children and Adults With RASopathies	nan	RECRUITING
IVF Outcome in Polycystic Ovary Syndrome Patients	nan	UNKNOWN
Partial PTEN Deletion in Breast Cancer	nan	UNKNOWN
Study of Metabolic Modifications in Children With Noonan Syndrome	nan	COMPLETED
Clinical Genetics Branch Eligibility Screening Survey	nan	NOT_YET_RECRUITING
Molecular Analysis in Tissue Samples From Patients With Advanced or Metastatic Neuroendocrine Tumors	nan	UNKNOWN
Regulation of Lymphocyte Anti-tumor Response in Metastatic Patients Treated With the mTOR Inhibitor Everolimus	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a PPM1G binder may also engage these)

Protein	Name	Similarity
Q4R4V2	—	1.000	Q4R4V2 →
P79126	—	1.000	P79126 →
Q61074	—	1.000	Q61074 →
F1LNI5	—	1.000	F1LNI5 →
A0A7U2MSD6	—	0.987	A0A7U2MSD6 →
Q4WTH5	—	0.987	Q4WTH5 →
P49595	—	0.987	P49595 →
G0RT93	—	0.986	G0RT93 →
P13234	—	0.983	P13234 →
Q8R0F6	—	0.983	Q8R0F6 →
Q6YTI2	—	0.982	Q6YTI2 →
Q09173	—	0.982	Q09173 →
Q9H0C8	—	0.982	Q9H0C8 →
Q0IIF0	—	0.981	Q0IIF0 →
Q9Z1Z6	—	0.979	Q9Z1Z6 →
Q19775	—	0.979	Q19775 →
Q7K4Q5	—	0.979	Q7K4Q5 →
P20689	—	0.979	P20689 →
Q9H1H9	—	0.979	Q9H1H9 →
Q9M8R7	—	0.978	Q9M8R7 →
O70551	—	0.978	O70551 →
P39966	—	0.978	P39966 →
Q9SA22	—	0.978	Q9SA22 →
Q5RD27	—	0.978	Q5RD27 →
Q5XIK8	—	0.978	Q5XIK8 →
Q9Y4B4	—	0.978	Q9Y4B4 →
D3ZA12	—	0.977	D3ZA12 →
ASH2L	Set1/Ash2 histone methyltransferase complex subunit ASH2	0.977	landscape →
A3KFM7	—	0.977	A3KFM7 →
O54781	—	0.977	O54781 →